Quell Therapeutics has announced the appointment of Iain McGill as chief executive. Iain is a leading pharmaceutical executive with extensive relevant experience having spent the majority of his 25 years in the industry in the area of solid organ and cell t
ransplantation.
He brings to Quell Therapeutics a track record established over 25 years in the pharmaceutical business; 15 of which focused specifically in the field of solid organ and cell transplantation. Prior to joining the company, he served as senior vice president Europe and rest of wo
rld for Jazz Pharmaceuticals, an international biopharmaceutical company, where he was instrumental in growing an international footprint for Jazz and was an integral member of the management team.
Iain says that he is “delighted to be leading such an exciting company. With Syncona’s vision and the backing of leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases from KCL, UCL, and Hannover Medical School, Quell Therapeutics has a real opportunity to bring transformational therapies to patients who are in need of safer and more effective therapies to manage their conditions.”
